$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

$ptgx Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000137712117000003 Filed on May 10, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.120M	$2.990M	$1.420M
YoY Change	122.86%	110.56%	178.43%
% of Gross Profit
Research & Development	$12.01M	$11.28M	$5.625M
YoY Change	110.8%	100.57%	158.03%
% of Gross Profit
Depreciation & Amortization	$90.00K	$88.00K	$73.00K
YoY Change	0.0%	20.55%	21.67%
% of Gross Profit
Operating Expenses	$15.13M	$14.27M	$7.040M
YoY Change	113.38%	102.74%	161.71%
Operating Profit	-$15.13M	-$14.27M	-$7.040M
YoY Change	113.38%	102.74%	161.81%
Interest Expense	$150.0K	$170.0K	-$4.710M
YoY Change	400.0%	-103.61%	47000.0%
% of Operating Profit
Other Income/Expense, Net	$0.00		$0.00
YoY Change	-100.0%
Pretax Income	-$14.98M	-$14.10M	-$11.75M
YoY Change	110.99%	20.0%	335.19%
Income Tax
% Of Pretax Income
Net Earnings	-$14.98M	-$14.10M	-$11.75M
YoY Change	111.03%	20.04%	335.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$887.4K	-$840.8K	-$801.5K
COMMON SHARES
Basic Shares Outstanding	16.86M shares	16.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.50M	$63.20M	$29.00M
YoY Change	219.31%	117.93%
Cash & Equivalents	$10.37M	$9.517M	$28.63M
Short-Term Investments	$54.10M	$53.70M	$400.0K
Other Short-Term Assets	$1.700M	$1.800M	$600.0K
YoY Change	240.0%	200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$69.13M	$67.55M	$30.90M
YoY Change	208.36%	118.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$903.0K	$641.0K	$800.0K
YoY Change	50.75%	-19.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$14.00M
YoY Change
Other Assets	$0.00	$34.00K	$200.0K
YoY Change	-100.0%	-83.0%
Total Long-Term Assets	$1.353M	$15.13M	$1.000M
YoY Change	-35.54%	1412.5%
TOTAL ASSETS
Total Short-Term Assets	$69.13M	$67.55M	$30.90M
Total Long-Term Assets	$1.353M	$15.13M	$1.000M
Total Assets	$70.48M	$82.67M	$31.90M
YoY Change	187.48%	159.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.639M	$1.132M	$1.900M
YoY Change	83.14%	-40.42%
Accrued Expenses	$6.727M	$6.647M	$2.300M
YoY Change	152.04%	189.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.366M	$7.779M	$4.500M
YoY Change	127.88%	72.87%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.000M
YoY Change		-100.0%
Other Long-Term Liabilities	$100.0K
YoY Change
Total Long-Term Liabilities	$100.0K	$0.00	$1.000M
YoY Change		-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.366M	$7.779M	$4.500M
Total Long-Term Liabilities	$100.0K	$0.00	$1.000M
Total Liabilities	$9.449M	$7.800M	$5.500M
YoY Change	129.9%	41.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$93.67M	-$78.70M
YoY Change	102.49%
Common Stock	$154.7M	$153.6M
YoY Change	97811.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$61.03M	$74.89M	$26.40M
YoY Change
Total Liabilities & Shareholders Equity	$70.48M	$82.67M	$31.90M
YoY Change	187.48%	159.16%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$14.98M	-$14.10M	-$11.75M
YoY Change	111.03%	20.04%	335.56%
Depreciation, Depletion And Amortization	$90.00K	$88.00K	$73.00K
YoY Change	0.0%	20.55%	21.67%
Cash From Operating Activities	-$12.32M	-$10.36M	-$5.240M
YoY Change	52.66%	97.71%	115.64%
INVESTING ACTIVITIES
Capital Expenditures	-$370.0K	$48.00K	$251.0K
YoY Change	1133.33%	-80.88%	-2610.0%
Acquisitions
YoY Change
Other Investing Activities	$13.46M	-$1.200M	$7.400M
YoY Change	-323.96%	-116.22%
Cash From Investing Activities	$13.09M	-$1.250M	$7.150M
YoY Change	-316.72%	-117.48%	-71600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	90.00K	370.0K	22.63M
YoY Change	-112.0%	-98.37%
NET CHANGE
Cash From Operating Activities	-12.32M	-10.36M	-5.240M
Cash From Investing Activities	13.09M	-1.250M	7.150M
Cash From Financing Activities	90.00K	370.0K	22.63M
Net Change In Cash	860.0K	-11.24M	24.54M
YoY Change	-105.79%	-145.8%	-1105.74%
FREE CASH FLOW
Cash From Operating Activities	-$12.32M	-$10.36M	-$5.240M
Capital Expenditures	-$370.0K	$48.00K	$251.0K
Free Cash Flow	-$11.95M	-$10.41M	-$5.491M
YoY Change	48.63%	89.55%	126.9%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001377121
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16856416	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	PROTAGONIST THERAPEUTICS, INC
CY2017Q1	dei	Trading Symbol TradingSymbol	PTGX
CY2016Q1	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	40000	USD
CY2017Q1	ptgx	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	0	USD
CY2016Q4	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	3617000	USD
CY2017Q1	ptgx	Accrued Clinical And Research Related Expenses Current AccruedClinicalAndResearchRelatedExpensesCurrent	4960000	USD
CY2015Q4	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	4065000	USD
CY2016Q1	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	28639000	USD
CY2016Q4	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	21094000	USD
CY2017Q1	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents CashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	9977000	USD
CY2016Q1	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	24574000	USD
CY2017Q1	ptgx	Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11117000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	85241000	USD
CY2017Q1	ptgx	Cash Equivalents And Available For Sale Securities Amortized Cost CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost	75408000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	85169000	USD
CY2017Q1	ptgx	Cash Equivalents And Available For Sale Securities Fair Value CashEquivalentsAndAvailableForSaleSecuritiesFairValue	75322000	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	2000	USD
CY2017Q1	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Gain CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGain	0	USD
CY2016Q4	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	74000	USD
CY2017Q1	ptgx	Cash Equivalents And Available For Sale Securities Gross Unrealized Loss CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLoss	86000	USD
CY2016Q1	ptgx	Effectof Exchange Rateon Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents EffectofExchangeRateonCashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	35000	USD
CY2017Q1	ptgx	Effectof Exchange Rateon Cash Cash Equivalents Restricted Cashand Restricted Cash Equivalents EffectofExchangeRateonCashCashEquivalentsRestrictedCashandRestrictedCashEquivalents	115000	USD
CY2016Q1	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	4719000	USD
CY2017Q1	ptgx	Fair Value Adjustment Of Tranche And Warrants FairValueAdjustmentOfTrancheAndWarrants	0	USD
CY2016Q1	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	4194000	USD
CY2017Q1	ptgx	Fair Value Adjustment Of Tranche Liability FairValueAdjustmentOfTrancheLiability	0	USD
CY2016Q1	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	575000	USD
CY2017Q1	ptgx	Increase Decrease In Research And Development Tax Incentive Receivable IncreaseDecreaseInResearchAndDevelopmentTaxIncentiveReceivable	102000	USD
CY2016Q2	ptgx	Remeasured Fair Value Of Warrants RemeasuredFairValueOfWarrants	1000000	USD
CY2016Q4	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	2241000	USD
CY2017Q1	ptgx	Research And Development Tax Incentive Receivable ResearchAndDevelopmentTaxIncentiveReceivable	2480000	USD
CY2016Q1	ptgx	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2016Q4	ptgx	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2017Q1	ptgx	Restricted Cash Current RestrictedCashCurrent	10000	USD
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16834647	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16722280	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16834647	shares
CY2017Q1	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	0	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1163000	USD
CY2017Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	847000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5272000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6647000	USD
CY2016Q1	ptgx	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2016Q4	ptgx	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2017Q1	ptgx	Restricted Cash Noncurrent RestrictedCashNoncurrent	450000	USD
CY2016Q1	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5800000	USD
CY2016Q1	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	5837000	USD
CY2017Q1	ptgx	Settlement Of Fair Value Of Redeemable Convertible Preferred Stock Liability SettlementOfFairValueOfRedeemableConvertiblePreferredStockLiability	0	USD
CY2016Q1	ptgx	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	135000	USD
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1132000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-82000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-122000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1420000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	115000	USD
CY2017Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	732000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-245000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	152393000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	153610000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	843000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9498843	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2306482	shares
CY2016Q4	us-gaap	Assets Assets	93990000	USD
CY2017Q1	us-gaap	Assets Assets	82673000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	83244000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	67548000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	85169000	USD
CY2017Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	75322000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	56515000	USD
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	53731000	USD
CY2016	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	10150000	USD
CY2017Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	14000000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	118000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28629000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21084000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9517000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	18504000	USD
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16722280	shares
CY2017Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	7591000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-151000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	617000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1359000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-943000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11740000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13878000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	88000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-40.96
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	11300000	USD
CY2017Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M28D
CY2016Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	525000	USD
CY2017Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1415000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2991000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	593000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1586000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	12000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	172000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93990000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82673000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6435000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7779000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	22631000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	374000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	7147000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1250000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5239000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10356000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-11747000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-14101000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11787000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14101000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	7040000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	14273000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7040000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14273000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	13817000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2054000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1995000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1936000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1706000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	5401000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	725000	USD
CY2016Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	5272000	USD
CY2017Q1	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6647000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	120000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.57
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M9D
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	251000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	108000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	34000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	5000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-14000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	237000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8002000	USD
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3394000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1810000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	22488000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	7398000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	6800000	USD
CY2016Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	143000	USD
CY2017Q1	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	374000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	562000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5625000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11282000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-64593000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78694000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-78700000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	56000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	843000	USD
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.648
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.625
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.013
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0207
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.68
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	87555000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	74894000	USD
CY2016Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0689655
CY2016Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	40000	USD
CY2017Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	287800	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16766218	shares
CY2017Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and available-for-sale securities. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and to meet liquidity requirements. The Company’s cash equivalents and available-for-sale securities are managed by external managers within the guidelines of the Company’s investment policy. The Company’s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its portfolio of cash equivalents and available-for-sale securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, and highly rated corporate debt obligations and money market funds. The Company has not experienced any material credit losses on its investments. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accruals for research and development activities, stock-based compensation and income taxes. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results may differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001377121-17-000003-index-headers.html	Edgar Link	pending
0001377121-17-000003-index.html	Edgar Link	pending
0001377121-17-000003.txt	Edgar Link	pending
0001377121-17-000003-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ptgx-20170331.xml	Edgar Link	completed
ptgx-20170331.xsd	Edgar Link	pending
ptgx-20170331_cal.xml	Edgar Link	unprocessable
ptgx-20170331_def.xml	Edgar Link	unprocessable
ptgx-20170331_lab.xml	Edgar Link	unprocessable
ptgx-20170331_pre.xml	Edgar Link	unprocessable
ptgx10-qq12017.htm	Edgar Link	pending
ptgx10-qq1ex311.htm	Edgar Link	pending
ptgx10-qq1ex312.htm	Edgar Link	pending
ptgx10-qq1ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx

2017 Q2 Form 10-Q Financial Statement

#000137712117000003 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX Protagonist Therapeutics, Inc Stock $ptgx

2017 Q2 Form 10-Q Financial Statement

#000137712117000003 Filed on May 10, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTGX
Protagonist Therapeutics, Inc Stock $ptgx